后监管时代医院制剂产业强基固本的思考与对策

    Thoughts and Countermeasures on Strengthening the Foundation and Consolidating the Base of the Hospital Pharmaceutical Industry in the Post-Regulatory Era

    • 摘要:
      目的 聚焦新时期医院制剂监管方向和关注热点,基于监管现状为“十五五”医院制剂产业高质量发展建言献策。
      方法 以短语检索法查阅梳理“十四五”时期国家机构官网公开发布的医院制剂政策文件、提案建议复函及现行有效的核心法规文件,归纳总结其监管现状并为医院制剂产业发展提出参考建议。
      结果 新时期医院制剂监管政策导向和民生关注主要涉及审评审批、调剂使用、新药研发、成果转化、民族药传承发展、平台建设等领域;现行监管核心法规条款主要涉及审评审批、支付方式、调剂使用、制剂配制等领域,但部分法规文件陈旧。
      结论 应认识到医院制剂满足临床需求和产业化发展的重要价值,从新药研发与成果转化、风险监测、儿童特殊人群用药等方面强化其薄弱根基,推动医院制剂产业科学化、规范化、特色化发展。

       

      Abstract:
      OBJECTIVE To suggest for the high-quality development of the hospital preparation industry during the "15th Five-Year Plan" period, by focusing on the regulatory direction and key concerns of hospital preparations in the new era, and based on the current regulatory situation.
      METHODS By using the phrase search method to review and sort out the policy documents, proposal suggestions and replyed letters during the "14th Five-Year Plan" period as well as the currently effective core regulatory documents on hospital preparations publicly released by the official websites of national institutions, summarized the current regulatory situation and put forward reference suggestions for the development of the hospital preparation industry.
      RESULTS The regulatory policies and public concerns regarding hospital preparations in the new era mainly covered areas such as review and approval, dispensing and usage, new drug research and development, technology transfer, inheritance and development of ethnic medicines, and platform construction; the core regulatory provisions for hospital preparations currently in place mainly cover areas such as review and approval, payment methods, dispensing and use, and manufacture of preparations; however, some of the regulatory documents were outdated.
      CONCLUSION It is necessary to recognize the significant value of hospital preparations in meeting clinical needs and promoting industrialization, strengthen its weak foundation from aspects such as new drug research and development and technology transfer, risk monitoring, and medication for children and other special groups, promote the scientific, standardized and characteristic development of its industry.

       

    /

    返回文章
    返回